Analysts have been eager to weigh in on the Healthcare sector with new ratings on Galapagos (GLPG), Regeneron (REGN) and BeiGene (BGNE).
Galapagos (GLPG)
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Galapagos, with a price target of $138.00. The company’s shares closed last Friday at $120.36, close to its 52-week low of $112.00.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 10.7% and a 49.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Phasebio Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on Galapagos is a Hold with an average price target of $141.52, which is a 15.9% upside from current levels. In a report issued on October 27, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Regeneron (REGN)
In a report released today, Geoff Porges from Leerink Partners maintained a Buy rating on Regeneron, with a price target of $653.00. The company’s shares closed last Friday at $575.26.
According to TipRanks.com, Porges is a 3-star analyst with an average return of 3.3% and a 46.8% success rate. Porges covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Pandion Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $673.60 average price target, a 14.6% upside from current levels. In a report issued on October 28, Piper Sandler also maintained a Buy rating on the stock with a $675.00 price target.
BeiGene (BGNE)
In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on BeiGene, with a price target of $240.00. The company’s shares closed last Friday at $280.00.
According to TipRanks.com, Berens is a 5-star analyst with an average return of 15.2% and a 71.3% success rate. Berens covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Deciphera Pharmaceuticals, and Blueprint Medicines.
BeiGene has an analyst consensus of Moderate Buy, with a price target consensus of $244.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
